vs
Krystal Biotech, Inc.（KRYS）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
STURM RUGER & CO INC的季度营收约是Krystal Biotech, Inc.的1.4倍（$151.1M vs $107.1M），Krystal Biotech, Inc.同比增速更快（17.5% vs 3.6%），Krystal Biotech, Inc.自由现金流更多（$75.4M vs $12.3M），过去两年Krystal Biotech, Inc.的营收复合增速更高（53.8% vs 5.1%）
Krystal Biotech是一家处于临床阶段的生物技术企业，专注于研发和商业化针对罕见重症皮肤病的新型基因疗法，主要面向北美和欧洲市场，服务缺乏有效常规治疗方案的单基因皮肤病患者。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
KRYS vs RGR — 直观对比
营收规模更大
RGR
是对方的1.4倍
$107.1M
营收增速更快
KRYS
高出13.9%
3.6%
自由现金流更多
KRYS
多$63.0M
$12.3M
两年增速更快
KRYS
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $107.1M | $151.1M |
| 净利润 | $51.4M | — |
| 毛利率 | — | 17.8% |
| 营业利润率 | 41.5% | 2.3% |
| 净利率 | 48.0% | — |
| 营收同比 | 17.5% | 3.6% |
| 净利润同比 | 13.0% | — |
| 每股收益（稀释后） | $1.69 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KRYSRGR
| Q4 25 | $107.1M | $151.1M | ||
| Q3 25 | $97.8M | $126.8M | ||
| Q2 25 | $96.0M | $132.5M | ||
| Q1 25 | $88.2M | $135.7M | ||
| Q4 24 | $91.1M | $145.8M | ||
| Q3 24 | $83.8M | $122.3M | ||
| Q2 24 | $70.3M | $130.8M | ||
| Q1 24 | $45.3M | $136.8M |
净利润KRYSRGR
| Q4 25 | $51.4M | — | ||
| Q3 25 | $79.4M | $1.6M | ||
| Q2 25 | $38.3M | $-17.2M | ||
| Q1 25 | $35.7M | $7.8M | ||
| Q4 24 | $45.5M | — | ||
| Q3 24 | $27.2M | $4.7M | ||
| Q2 24 | $15.6M | $8.3M | ||
| Q1 24 | $932.0K | $7.1M |
毛利率KRYSRGR
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | 15.1% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 22.0% | ||
| Q4 24 | — | 22.8% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 22.3% | ||
| Q1 24 | — | 21.5% |
营业利润率KRYSRGR
| Q4 25 | 41.5% | 2.3% | ||
| Q3 25 | 42.3% | -2.7% | ||
| Q2 25 | 40.9% | -15.6% | ||
| Q1 25 | 41.0% | 6.2% | ||
| Q4 24 | 45.4% | 7.8% | ||
| Q3 24 | 26.8% | 3.1% | ||
| Q2 24 | 12.2% | 6.9% | ||
| Q1 24 | -14.8% | 5.5% |
净利率KRYSRGR
| Q4 25 | 48.0% | — | ||
| Q3 25 | 81.2% | 1.2% | ||
| Q2 25 | 39.9% | -13.0% | ||
| Q1 25 | 40.5% | 5.7% | ||
| Q4 24 | 49.9% | — | ||
| Q3 24 | 32.4% | 3.9% | ||
| Q2 24 | 22.2% | 6.3% | ||
| Q1 24 | 2.1% | 5.2% |
每股收益（稀释后）KRYSRGR
| Q4 25 | $1.69 | $0.22 | ||
| Q3 25 | $2.66 | $0.10 | ||
| Q2 25 | $1.29 | $-1.05 | ||
| Q1 25 | $1.20 | $0.46 | ||
| Q4 24 | $1.53 | $0.62 | ||
| Q3 24 | $0.91 | $0.28 | ||
| Q2 24 | $0.53 | $0.47 | ||
| Q1 24 | $0.03 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $496.3M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $283.8M |
| 总资产 | $1.3B | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资KRYSRGR
| Q4 25 | $496.3M | $92.5M | ||
| Q3 25 | $392.6M | $80.8M | ||
| Q2 25 | $353.8M | $101.4M | ||
| Q1 25 | $308.8M | $108.3M | ||
| Q4 24 | $344.9M | $105.5M | ||
| Q3 24 | $374.0M | $96.0M | ||
| Q2 24 | $345.8M | $105.6M | ||
| Q1 24 | $359.0M | $115.3M |
股东权益KRYSRGR
| Q4 25 | $1.2B | $283.8M | ||
| Q3 25 | $1.1B | $279.6M | ||
| Q2 25 | $1.0B | $289.3M | ||
| Q1 25 | $984.7M | $321.5M | ||
| Q4 24 | $946.4M | $319.6M | ||
| Q3 24 | $885.8M | $314.9M | ||
| Q2 24 | $838.9M | $321.5M | ||
| Q1 24 | $799.2M | $332.0M |
总资产KRYSRGR
| Q4 25 | $1.3B | $342.0M | ||
| Q3 25 | $1.2B | $342.3M | ||
| Q2 25 | $1.1B | $349.5M | ||
| Q1 25 | $1.1B | $379.0M | ||
| Q4 24 | $1.1B | $384.0M | ||
| Q3 24 | $982.3M | $373.5M | ||
| Q2 24 | $917.7M | $376.7M | ||
| Q1 24 | $853.3M | $385.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $77.5M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $75.4M | $12.3M |
| 自由现金流率自由现金流/营收 | 70.4% | 8.2% |
| 资本支出强度资本支出/营收 | 2.0% | 2.1% |
| 现金转化率经营现金流/净利润 | 1.51× | — |
| 过去12个月自由现金流最近4个季度 | $188.9M | $38.5M |
8季度趋势，按日历期对齐
经营现金流KRYSRGR
| Q4 25 | $77.5M | $15.5M | ||
| Q3 25 | $39.7M | $12.9M | ||
| Q2 25 | $52.7M | $14.7M | ||
| Q1 25 | $31.0M | $11.1M | ||
| Q4 24 | $52.8M | $20.0M | ||
| Q3 24 | $58.9M | $9.4M | ||
| Q2 24 | $-4.2M | $18.7M | ||
| Q1 24 | $15.9M | $7.3M |
自由现金流KRYSRGR
| Q4 25 | $75.4M | $12.3M | ||
| Q3 25 | $38.0M | $7.0M | ||
| Q2 25 | $50.8M | $9.1M | ||
| Q1 25 | $24.8M | $10.0M | ||
| Q4 24 | $52.0M | $16.4M | ||
| Q3 24 | $57.8M | $2.6M | ||
| Q2 24 | $-5.3M | $10.1M | ||
| Q1 24 | $14.6M | $5.6M |
自由现金流率KRYSRGR
| Q4 25 | 70.4% | 8.2% | ||
| Q3 25 | 38.8% | 5.5% | ||
| Q2 25 | 52.9% | 6.9% | ||
| Q1 25 | 28.1% | 7.4% | ||
| Q4 24 | 57.1% | 11.2% | ||
| Q3 24 | 69.0% | 2.1% | ||
| Q2 24 | -7.5% | 7.7% | ||
| Q1 24 | 32.3% | 4.1% |
资本支出强度KRYSRGR
| Q4 25 | 2.0% | 2.1% | ||
| Q3 25 | 1.7% | 4.6% | ||
| Q2 25 | 2.0% | 4.2% | ||
| Q1 25 | 7.0% | 0.8% | ||
| Q4 24 | 0.9% | 2.5% | ||
| Q3 24 | 1.2% | 5.5% | ||
| Q2 24 | 1.6% | 6.6% | ||
| Q1 24 | 2.8% | 1.3% |
现金转化率KRYSRGR
| Q4 25 | 1.51× | — | ||
| Q3 25 | 0.50× | 8.15× | ||
| Q2 25 | 1.38× | — | ||
| Q1 25 | 0.87× | 1.43× | ||
| Q4 24 | 1.16× | — | ||
| Q3 24 | 2.17× | 1.98× | ||
| Q2 24 | -0.27× | 2.27× | ||
| Q1 24 | 17.05× | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KRYS
暂无分部数据
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
